Status:
COMPLETED
Pneumococcal Conjugate Vaccine Followup
Lead Sponsor:
William Pomat
Collaborating Sponsors:
The University of Western Australia
Conditions:
Immune Tolerance
Eligibility:
All Genders
3-5 years
Phase:
PHASE2
Brief Summary
Recently, controversy has emerged regarding the role of the 23vPPV in infants due to potential immunological hypo-responsiveness (i.e. a poorer immune response to repeat vaccination). Although previou...
Eligibility Criteria
Inclusion
- PNG Infants aged 3 to 5 yrs of age who participated in previous PNG Neonatal PCV study and received PPV between 9 and 12 months of age, or age- and sex-matched controls who live in the same villages or urban area
- Informed parental/guardian consent
Exclusion
- Known HIV infection or other immunosuppressive condition or treatment.
- Prior receipt of 2 doses of pneumococcal polysaccharide vaccine
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT01414504
Start Date
December 1 2009
End Date
September 1 2012
Last Update
September 17 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PNG Institute of Medical Research
Goroka, Eastern Highlands Province, Papua New Guinea, 441